

Kidney Cancer Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Therapeutic Class (Targeted Therapy, Immunotherapy, Chemotherapy), By Pharmacologic Class (Angiogenesis Inhibitors, Monoclonal Antibodies, mTOR Inhibitors, Cytokine Immunotherapy (IL-2)), By Region, Competition

<https://marketpublishers.com/r/K14D972EA964EN.html>

Date: October 2023

Pages: 190

Price: US\$ 4,900.00 (Single User License)

ID: K14D972EA964EN

Abstracts

The Global Kidney Cancer Drugs Market achieved a valuation of USD 6.28 Billion in 2022, and it is expected to experience substantial growth in the forecast period, projecting a Compound Annual Growth Rate (CAGR) of 6.50% and is expected to reach USD 9.18 Billion by 2028. Kidney cancer, medically known as renal cell carcinoma (RCC), is a complex disease originating in the kidneys, vital organs responsible for filtering waste and excess fluids from the blood to produce urine. The treatment of kidney cancer is a challenging task, demanding effective strategies. The growth and evolution of the kidney cancer drugs market are being propelled by several key drivers as medical research advances and pharmaceutical innovation accelerates.

Key Market Drivers:

1. **Advancements in Research and Development:** Significant resources are being invested by pharmaceutical companies, academic institutions, and research organizations to gain a deep understanding of the underlying biology of kidney cancer. This investment has led to the identification of crucial molecular pathways, genetic mutations, and biomarkers responsible for driving the development and progression of kidney cancer. These advancements have laid the foundation for the development of targeted therapies, which focus on inhibiting specific molecules or pathways involved in

cancer growth. Examples include tyrosine kinase inhibitors (TKIs) and mTOR inhibitors, which have transformed kidney cancer treatment by providing more effective and less toxic therapies.

2. **Immunotherapy Revolution:** The advent of immunotherapies has brought about a revolution in the treatment of various cancers, including kidney cancer. Immune checkpoint inhibitors, such as PD-1 and PD-L1 inhibitors, have shown remarkable efficacy by harnessing the body's immune system to recognize and attack cancer cells. These therapies have not only extended survival rates but have also paved the way for innovative combination therapies. Researchers are actively exploring how to synergize targeted therapies with immunotherapies to achieve even more robust responses. The emergence of immunotherapies has ushered in a new era of cancer treatment.

3. **Rising Clinical Trial Innovation:** Clinical trials are fundamental in evaluating the safety and efficacy of new kidney cancer drugs. Innovative trial designs, incorporating biomarker-driven endpoints and adaptive trial designs, are propelling drug development forward. Biomarker-driven trials enable the selection of patients most likely to respond to a particular therapy, while adaptive trial designs allow real-time modifications based on accumulating data, enhancing trial efficiency and decision-making.

Key Market Challenges:

1. **Resistance and Treatment Heterogeneity:** Despite the progress made in targeted therapies and immunotherapies, the development of resistance to these treatments remains a significant challenge in kidney cancer. Tumors can adapt over time, rendering once-effective therapies ineffective. This highlights the need for continuous research to understand the mechanisms of resistance and develop strategies to overcome it. Moreover, kidney cancer is not a homogeneous disease, with different subtypes and genetic variations contributing to variations in treatment response. Developing therapies that are effective across diverse patient populations is a complex endeavor.

2. **Lack of Predictive Biomarkers:** The absence of reliable predictive biomarkers hinders the development of effective kidney cancer drugs. Biomarkers that can accurately identify patients likely to respond to a particular treatment are essential for personalized medicine approaches. Currently, no single biomarker has demonstrated consistent predictive value across all patients and treatment modalities. The lack of reliable biomarkers makes it challenging for healthcare professionals to make informed treatment decisions.

3. Immune-Related Adverse Events (irAEs): Immunotherapies, while transformative in cancer treatment, can lead to immune-related adverse events (irAEs) as they activate the immune system. These events can affect various organs, necessitating careful management to balance immune activation against potential harm. The occurrence and severity of irAEs can impact patient compliance, quality of life, and overall treatment success.

Key Market Trends:

1. Personalized Medicine Revolution: The advent of personalized medicine is offering promising prospects for improved patient outcomes in kidney cancer treatment. Precision oncology tailors interventions based on individual genetic profiles and biomarker expression, moving away from a one-size-fits-all approach. Advancements in genomics and molecular diagnostics enable oncologists to identify specific genetic mutations or alterations driving a patient's kidney cancer. This information guides the prescription of targeted therapies with a higher likelihood of success, enhancing drug efficacy and minimizing adverse effects.

2. Combination Therapies: Combining multiple treatments simultaneously or sequentially is emerging as a powerful strategy to enhance treatment efficacy and overcome resistance in kidney cancer. The synergy achieved by combining targeted therapies with immunotherapies or other treatment modalities offers a multifaceted approach to attacking cancer cells. The exploration of novel combinations that maximize treatment outcomes is driving the demand for kidney cancer drugs. The potential to achieve better responses and prolonged disease control is spurring collaborative efforts to identify the optimal synergy between different therapeutic approaches.

Segmental Insights:

Therapeutic Class Insights: In 2022, the immunotherapy segment dominated the Kidney Cancer Drugs Market, holding the largest share. The increasing preference for innovative immunotherapies and immune-oncologic drugs is driving the use of targeted therapies, particularly in specific patient subpopulations or as later lines of treatment, which is boosting demand.

Regional Insights: North America has established itself as the leader in the Global Kidney Cancer Drugs Market. This can be attributed to widespread healthcare spending and favorable reimbursement regulations for therapy. Furthermore, the high prevalence of smoking, hypertension, and diabetes among its population, along with the presence

of major pharmaceutical manufacturers, positions Asia-Pacific to experience the highest growth in the kidney cancer drugs market during the forecast period.

Key Market Players

Novartis AG

Pfizer Inc.

Bayer AG

Genentech Inc.

Bristol-Myers Squibb

Eisai Co., Ltd.

Exelixis Inc

Prometheus Laboratories Inc

Glaxosmithkline PLC.

F. Hoffmann-LA Roche AG

Report Scope:

In this report, the Global Kidney Cancer Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Kidney Cancer Drugs Market, By Therapeutic Class:

Targeted Therapy

Immunotherapy

Chemotherapy

Kidney Cancer Drugs Market, By Pharmacologic Class:

Angiogenesis Inhibitors

Monoclonal Antibodies

mTOR Inhibitors

Cytokine Immunotherapy (IL-2)

Global Kidney Cancer Drugs Market, By Region:

North America

United States

Canada

Mexico

Asia-Pacific

China

India

South Korea

Australia

Japan

Europe

Germany

France

United Kingdom

Spain

Italy

South America

Brazil

Argentina

Colombia

Middle East & Africa

South Africa

Saudi Arabia

UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Kidney Cancer Drugs Market.

Available Customizations:

Global Kidney Cancer Drugs Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Contents

1. PRODUCT OVERVIEW

- 1.1. Market Definition
- 1.2. Scope of the Market
 - 1.2.1. Markets Covered
 - 1.2.2. Years Considered for Study
 - 1.2.3. Key Market Segmentations

2. RESEARCH METHODOLOGY

- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations

3. EXECUTIVE SUMMARY

- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends

4. VOICE OF CUSTOMER

5. GLOBAL KIDNEY CANCER DRUGS MARKET OUTLOOK

- 5.1. Market Size & Forecast
 - 5.1.1. By Value
- 5.2. Market Share & Forecast
 - 5.2.1. By Therapeutic Class (Targeted Therapy, Immunotherapy, Chemotherapy)
 - 5.2.2. By Pharmacologic Class (Angiogenesis Inhibitors, Monoclonal Antibodies, mTOR Inhibitors, Cytokine Immunotherapy (IL-2))

- 5.2.3. By Company (2022)
- 5.2.4. By Region
- 5.3. Market Map

6. NORTH AMERICA KIDNEY CANCER DRUGS MARKET OUTLOOK

- 6.1. Market Size & Forecast
 - 6.1.1. By Value
- 6.2. Market Share & Forecast
 - 6.2.1. By Therapeutic Class
 - 6.2.2. By Pharmacologic Class
 - 6.2.3. By Country
- 6.3. North America: Country Analysis
 - 6.3.1. United States Kidney Cancer Drugs Market Outlook
 - 6.3.1.1. Market Size & Forecast
 - 6.3.1.1.1. By Value
 - 6.3.1.2. Market Share & Forecast
 - 6.3.1.2.1. By Therapeutic Class
 - 6.3.1.2.2. By Pharmacologic Class
 - 6.3.2. Mexico Kidney Cancer Drugs Market Outlook
 - 6.3.2.1. Market Size & Forecast
 - 6.3.2.1.1. By Value
 - 6.3.2.2. Market Share & Forecast
 - 6.3.2.2.1. By Therapeutic Class
 - 6.3.2.2.2. By Pharmacologic Class
 - 6.3.3. Canada Kidney Cancer Drugs Market Outlook
 - 6.3.3.1. Market Size & Forecast
 - 6.3.3.1.1. By Value
 - 6.3.3.2. Market Share & Forecast
 - 6.3.3.2.1. By Therapeutic Class
 - 6.3.3.2.2. By Pharmacologic Class

7. EUROPE KIDNEY CANCER DRUGS MARKET OUTLOOK

- 7.1. Market Size & Forecast
 - 7.1.1. By Value & Volume
- 7.2. Market Share & Forecast
 - 7.2.1. By Therapeutic Class
 - 7.2.2. By Pharmacologic Class

7.2.3. By Country

7.3. Europe: Country Analysis

7.3.1. France Kidney Cancer Drugs Market Outlook

7.3.1.1. Market Size & Forecast

7.3.1.1.1. By Value

7.3.1.2. Market Share & Forecast

7.3.1.2.1. By Therapeutic Class

7.3.1.2.2. By Pharmacologic Class

7.3.2. Germany Kidney Cancer Drugs Market Outlook

7.3.2.1. Market Size & Forecast

7.3.2.1.1. By Value

7.3.2.2. Market Share & Forecast

7.3.2.2.1. By Therapeutic Class

7.3.2.2.2. By Pharmacologic Class

7.3.3. United Kingdom Kidney Cancer Drugs Market Outlook

7.3.3.1. Market Size & Forecast

7.3.3.1.1. By Value

7.3.3.2. Market Share & Forecast

7.3.3.2.1. By Therapeutic Class

7.3.3.2.2. By Pharmacologic Class

7.3.4. Italy Kidney Cancer Drugs Market Outlook

7.3.4.1. Market Size & Forecast

7.3.4.1.1. By Value

7.3.4.2. Market Share & Forecast

7.3.4.2.1. By Therapeutic Class

7.3.4.2.2. By Pharmacologic Class

7.3.5. Spain Kidney Cancer Drugs Market Outlook

7.3.5.1. Market Size & Forecast

7.3.5.1.1. By Value

7.3.5.2. Market Share & Forecast

7.3.5.2.1. By Therapeutic Class

7.3.5.2.2. By Pharmacologic Class

8. ASIA-PACIFIC KIDNEY CANCER DRUGS MARKET OUTLOOK

8.1. Market Size & Forecast

8.1.1. By Value & Volume

8.2. Market Share & Forecast

8.2.1. By Therapeutic Class

- 8.2.2. By Pharmacologic Class
- 8.2.3. By Country
- 8.3. Asia-Pacific: Country Analysis
 - 8.3.1. China Kidney Cancer Drugs Market Outlook
 - 8.3.1.1. Market Size & Forecast
 - 8.3.1.1.1. By Value
 - 8.3.1.2. Market Share & Forecast
 - 8.3.1.2.1. By Therapeutic Class
 - 8.3.1.2.2. By Pharmacologic Class
 - 8.3.2. India Kidney Cancer Drugs Market Outlook
 - 8.3.2.1. Market Size & Forecast
 - 8.3.2.1.1. By Value
 - 8.3.2.2. Market Share & Forecast
 - 8.3.2.2.1. By Therapeutic Class
 - 8.3.2.2.2. By Pharmacologic Class
 - 8.3.3. South Korea Kidney Cancer Drugs Market Outlook
 - 8.3.3.1. Market Size & Forecast
 - 8.3.3.1.1. By Value
 - 8.3.3.2. Market Share & Forecast
 - 8.3.3.2.1. By Therapeutic Class
 - 8.3.3.2.2. By Pharmacologic Class
 - 8.3.4. Japan Kidney Cancer Drugs Market Outlook
 - 8.3.4.1. Market Size & Forecast
 - 8.3.4.1.1. By Value
 - 8.3.4.2. Market Share & Forecast
 - 8.3.4.2.1. By Therapeutic Class
 - 8.3.4.2.2. By Pharmacologic Class
 - 8.3.5. Australia Kidney Cancer Drugs Market Outlook
 - 8.3.5.1. Market Size & Forecast
 - 8.3.5.1.1. By Value
 - 8.3.5.2. Market Share & Forecast
 - 8.3.5.2.1. By Therapeutic Class
 - 8.3.5.2.2. By Pharmacologic Class

9. SOUTH AMERICA KIDNEY CANCER DRUGS MARKET OUTLOOK

- 9.1. Market Size & Forecast
 - 9.1.1. By Value
- 9.2. Market Share & Forecast

- 9.2.1. By Therapeutic Class
- 9.2.2. By Pharmacologic Class
- 9.2.3. By Country
- 9.3. South America: Country Analysis
 - 9.3.1. Brazil Kidney Cancer Drugs Market Outlook
 - 9.3.1.1. Market Size & Forecast
 - 9.3.1.1.1. By Value
 - 9.3.1.2. Market Share & Forecast
 - 9.3.1.2.1. By Therapeutic Class
 - 9.3.1.2.2. By Pharmacologic Class
 - 9.3.2. Argentina Kidney Cancer Drugs Market Outlook
 - 9.3.2.1. Market Size & Forecast
 - 9.3.2.1.1. By Value
 - 9.3.2.2. Market Share & Forecast
 - 9.3.2.2.1. By Therapeutic Class
 - 9.3.2.2.2. By Pharmacologic Class
 - 9.3.3. Colombia Kidney Cancer Drugs Market Outlook
 - 9.3.3.1. Market Size & Forecast
 - 9.3.3.1.1. By Value
 - 9.3.3.2. Market Share & Forecast
 - 9.3.3.2.1. By Therapeutic Class
 - 9.3.3.2.2. By Pharmacologic Class

10. MIDDLE EAST AND AFRICA KIDNEY CANCER DRUGS MARKET OUTLOOK

- 10.1. Market Size & Forecast
 - 10.1.1. By Value
- 10.2. Market Share & Forecast
 - 10.2.1. By Therapeutic Class
 - 10.2.2. By Pharmacologic Class
 - 10.2.3. By Country
- 10.3. MEA: Country Analysis
 - 10.3.1. South Africa Kidney Cancer Drugs Market Outlook
 - 10.3.1.1. Market Size & Forecast
 - 10.3.1.1.1. By Value
 - 10.3.1.2. Market Share & Forecast
 - 10.3.1.2.1. By Therapeutic Class
 - 10.3.1.2.2. By Pharmacologic Class
 - 10.3.2. Saudi Arabia Kidney Cancer Drugs Market Outlook

- 10.3.2.1. Market Size & Forecast
 - 10.3.2.1.1. By Value
- 10.3.2.2. Market Share & Forecast
 - 10.3.2.2.1. By Therapeutic Class
 - 10.3.2.2.2. By Pharmacologic Class
- 10.3.3. UAE Kidney Cancer Drugs Market Outlook
 - 10.3.3.1. Market Size & Forecast
 - 10.3.3.1.1. By Value
 - 10.3.3.2. Market Share & Forecast
 - 10.3.3.2.1. By Therapeutic Class
 - 10.3.3.2.2. By Pharmacologic Class

11. MARKET DYNAMICS

- 11.1. Drivers
- 11.2. Challenges

12. MARKET TRENDS & DEVELOPMENTS

- 12.1. Recent Developments
- 12.2. Product Launches
- 12.3. Mergers & Acquisitions

13. PESTLE ANALYSIS

14. PORTER'S FIVE FORCES ANALYSIS

- 14.1. Competition in the Industry
- 14.2. Potential of New Entrants
- 14.3. Power of Suppliers
- 14.4. Power of Customers
- 14.5. Threat of Substitute Product

15. COMPETITIVE LANDSCAPE

- 15.1. Business Overview
- 15.2. Company Snapshot
- 15.3. Products & Services

15.4. Financials (In case of listed companies)

15.5. Recent Developments

15.6. SWOT Analysis

15.6.1. Novartis AG

15.6.2. Pfizer Inc.

15.6.3. Bayer AG

15.6.4. Genentech Inc.

15.6.5. Bristol-Myers Squibb

15.6.6. Eisai Co., Ltd.

15.6.7. Exelixis Inc

15.6.8. Prometheus Laboratories Inc

15.6.9. GlaxoSmithKline Plc

15.6.10. F. Hoffmann-LA Roche AG

16. STRATEGIC RECOMMENDATIONS

I would like to order

Product name: Kidney Cancer Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Therapeutic Class (Targeted Therapy, Immunotherapy, Chemotherapy), By Pharmacologic Class (Angiogenesis Inhibitors, Monoclonal Antibodies, mTOR Inhibitors, Cytokine Immunotherapy (IL-2), By Region, Competition

Product link: <https://marketpublishers.com/r/K14D972EA964EN.html>

Price: US\$ 4,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/K14D972EA964EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below
and fax the completed form to +44 20 7900 3970